Is DXCM a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Expansion beyond insulin users, with revenue (q1 2026) at ~$1.19 billion, up about 15% year over year. The bear case rests on the main risk is that DexCom carries a premium valuation built on continued high growth, so any slowdown, guidance cut, or margin disappointment can pressure the stock sharply. Analysts covering it are spread from $65.00 to $112.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The main risk is that DexCom carries a premium valuation built on continued high growth, so any slowdown, guidance cut, or margin disappointment can pressure the stock sharply. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $65.00, -14.5% from the $76.00 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Expansion beyond insulin users. DexCom's largest opportunity is extending CGM from insulin-dependent patients to the far larger type 2 non-insulin and consumer wellness populations. The most optimistic analyst target on DXCM is $112.00, +47.4% from the $76.00 price. That figure is only reachable if this thesis works close to its best case.

The main risk is that DexCom carries a premium valuation built on continued high growth, so any slowdown, guidance cut, or margin disappointment can pressure the stock sharply. Competition is significant: Abbott's FreeStyle Libre is a large, well-funded rival in CGM, and price competition or feature gaps could cost DexCom share, while Medtronic and newer entrants add pressure. Reimbursement is pivotal and outside DexCom's full control, so unfavorable coverage or pricing decisions by insurers and pharmacy-benefit managers could slow adoption. As a device maker, DexCom faces regulatory, manufacturing, and product-quality risks; a recall or supply issue would hurt. The push into the consumer and over-the-counter wellness market is newer and less proven than the medical diabetes business, so returns there are less certain. Acquisitions like NutriSense add integration risk. International expansion and currency swings add further variables. The most pessimistic published target is $65.00, -14.5% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

DexCom is a medical-device company that pioneered continuous glucose monitoring.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Expansion beyond insulin users) stalling in the reported numbers rather than in the narrative, the risk above (the main risk is that DexCom carries a premium valuation built on continued high growth, so any slowdown, guidance cut, or margin disappointment can pressure the stock sharply) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is durable double-digit growth, expansion beyond insulin users, new products, and widening insurance coverage. The bear case is a premium valuation that leaves little room for error, strong competition from Abbott, and reliance on reimbursement decisions. Weigh both against your portfolio and your comfort with a high-growth, high-expectation medical-device stock.

DexCom makes continuous glucose monitors, small wearable sensors that track glucose in real time and send readings to a phone or receiver. Its G7 platform serves people with type 1 and type 2 diabetes, and its over-the-counter Stelo product extends monitoring to people who do not use insulin. Most of its revenue comes from recurring sensor sales as users replace sensors regularly.

DexCom earns most of its revenue from recurring sales of CGM sensors, which users replace on a regular schedule, plus transmitters and related hardware. Because patients keep buying sensors once they are on the platform, the business has a durable, subscription-like quality. Revenue grows as more users adopt CGM and as coverage expands the affordable patient pool.